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Abstract
Background: Cardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular
dystrophy (DMD). We recently showed in a 12-month double-blind randomized controlled trial that adding
eplerenone to background medical therapy was cardioprotective in this population. The objective of this study
was to evaluate the safety and efficacy of longer-term eplerenone therapy in boys with DMD.
Results: Eleven subjects (phase 1 baseline median [range] age: 13 [7 – 25] years) from the original 12-month
trial at a single participating center were enrolled. Importantly, those who entered the extension study who
had been on eplerenone previously were significantly older than those who had originally been on placebo
(median age 10.5 vs. 18.0 years, p = 0.045). During an additional 24-month open-label extension study, all boys
received eplerenone 25 mg orally once daily to treat preclinical DMD cardiomyopathy, defined as evident myocardial
damage by late gadolinium enhancement cardiac magnetic resonance (LGE) with preserved ejection fraction (EF). The
threshold for potassium level, the primary safety measure, was not exceeded in any non-hemolyzed blood sample.
Over 24 months, left ventricular (LV) systolic strain, a more sensitive marker whose more negative values indicate
greater contractility significantly improved (median change -4.4%, IQR -5.8 to -0.9%) in younger subjects whereas
older subjects’ strain remained stable without significant worsening or improvement (median change 0.2%, IQR -1.1 to
4.3%). EF and extent of myocardial damage by LGE remained stable in both groups over 2 years.
Conclusions: Eplerenone offers effective and safe cardioprotection for boys with DMD, particularly when started
at a younger age. Eplerenone is a useful clinical therapeutic option, particularly if treatment is initiated earlier in
life when cardiac damage is minimal.
Trial registration: http://ClinicalTrials.gov identifier NCT01521546. Registered 26 January 2012.
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Background
Duchenne muscular dystrophy (DMD) affects approxi-
mately one of every 3,300 male births worldwide [1], and
is caused by mutations in the gene encoding for the
myocyte structural protein dystrophin [2]. Loss of dys-
trophin leads to inexorable damage to skeletal and cardiac
muscle, with cardiomyopathy increasingly recognized as a
major cause of death [3]. Animal models and human data
indicate that myocardial damage occurs well before func-
tional decline such as drop in left ventricular (LV) ejection
fraction (EF) is apparent [4], endorsing a strategy of treat-
ment while EF is preserved. A more sensitive measure of
cardiac function, LV systolic strain, has high reproducibil-
ity when measured by cardiac magnetic resonance [5] – a
critical feature when testing hypotheses in patients with
rare diseases to support efficient sample size reductions
[6] – and is abnormal in even the youngest boys with
DMD well before EF drops [7].
The availability of early, sensitive markers of myocar-
dial damage and dysfunction warrants effective therapies
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that can be readily instituted. While considerable advances
are being made in gene therapy [8], there remains a need
for immediately-available cardioprotective agents that can
serve DMD patients across mutations and with more
advanced skeletal myopathy. In a recently-published
randomized, double-blind 12-month clinical trial, we
demonstrated that adding the available mineralocorticoid
receptor antagonist drug eplerenone to background
therapy was superior to placebo in boys with DMD and
preserved EF in attenuating decline of cardiac function
[9]. In this open-label extension study, we tested the
hypothesis that eplerenone would have a durable bene-
fit on cardiac function preservation.
Methods
Study design, patient selection, and treatment
Enrollment in this open-label extension study
(NCT01521546) was offered to subjects completing their
participation in a 12 month placebo-controlled, ran-
domized, double-blind trial of eplerenone, noting that 2
of the original study centers (University of California
Los Angeles and Cincinnati Children’s Hospital Medical
Center) did not participate in the extension phase due
to subject preference, other trials, or limited resources
[9]. Twenty individuals age 7 years or older completed
the study from the Ohio State University (OSU) and
Nationwide Children’s Hospital (NCH) with a diagnosis
of DMD by mutation analysis, and were eligible for enroll-
ment in the extension phase. Included in the original
study were patients with evident myocardial damage by
late gadolinium enhancement CMR and preserved left
ventricular (LV) systolic dysfunction, defined by a CMR
LV ejection fraction of ≥ 45%. Background therapy at the
time of enrollment included angiotensin converting
enzyme inhibitor (ACEI) or angiotensin receptor blocker
(ARB) in all subjects, and none were previously on eplere-
none or spironolactone. Additional detail regarding inclu-
sion and exclusion criteria for the original study has been
described [9]. The extension study and associated data
safety monitoring plan were approved after institutional
review board review that required additional i) written
informed consent for subjects ≥18 years, ii) participant
assent plus parent or guardian permission for subjects age
14 to 17 years or iii) parental permission alone for partici-
pants younger than 14 years of age beyond what was pro-
vided for participation in the original study. Study data
were electronically captured and managed in accordance
with all regulatory requirements [10]. Treatment during
the extension phase consisted of eplerenone 25 mg, one
tablet by mouth daily.
Safety and efficacy assessments
All subjects had potassium meticulously monitored during
the initial 12 month study. Serum potassium measurements
were measured 1 month after entry in the extension phase
and then annually (i.e. at 24 and 36 months after baseline)
with additional measurements on a case-by-case basis as
dictated by each subject’s clinical team. Telephone follow-
up calls with drug diary review were conducted at 3, 6 and
9 months of each year in addition to annual subjects’ clinic
visits that included cardiology and neurology appointments.
Repeat CMR examination was performed annually for
up to 2 additional years using the identical protocol and
3 Tesla scanner (Siemens Verio, Erlangen, Germany) as
in the original study: 1) long axis and short-axis cine
imaging using steady-state free precession spanning the
LV to compute volumes and EF, mid-short-axis tagged
cine for computation of LV strain, and short-axis LGE
covering the LV for myocardial damage assessment.
LGE images used inversion-recovery gradient echo
acquisitions 12–15 min after intravenous administra-
tion of 0.2 mmol/kg gadopentetate dimeglumine in the
identical long axis and short axis planes as cine imaging,
with inversion time optimized to null normal myocardium.
As in the original study, efficacy was primarily assessed by
change in left ventricular circumferential strain with
secondary outcome measures of change in LV volumes,
ejection fraction, and myocardial extent of late gadolinium
enhancement. Adverse events and any admissions to hos-
pital because of heart failure, documented arrhythmias,
death, or hyperkalemia (potassium concentration ≥5.5
mmol/L) were recorded via telephone interviews and at
clinic visits.
Statistical analysis
The median values of the 12-month change (from 12 to
24 months) and 24-month change (from 12 to 36 months)
in strain, LV EF and LGE during this open-label extension
phase (from 12 to 36 months) were compared between
the eplerenone and placebo groups, using two-sample
Wilcoxon rank-sum tests.
Results
Patient disposition and demographic characteristics
Eleven of the original 20 male subjects who completed
the study from OSU/NCH elected to participate in the
open-label extension phase; 3 declined participation due
to unwillingness to undergo additional MRIs, and 6
declined participation due to difficulty with additional
travel. Median age at initial study entry was 13 years,
range 7 to 25 years; 6 participants were on placebo and
5 on eplerenone during the initial double-blind year of
the trial, with those originally on placebo significantly
younger than those originally on eplerenone (median
age 10.5 vs. 18.0 years, p = 0.045). Background ACEI or
ARB therapy was mandated prior to enrollment in the
original study, and continued in all participants (10 taking
an ACEI and 1 taking an ARB) throughout the extension
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phase. Five subjects were on a beta-blocker during the
extension study. Types and dosages of background
medications included: lisinopril (2.5 – 5 mg qd), enala-
pril (5 mg bid), losartan (25 mg qd), metoprolol succinate
(25 mg qd), carvedilol (3.125 mg bid). Dose changes in
background therapy over the course of the extension
study included one subject age 18 years originally
assigned to eplerenone whose enalapril dose was in-
creased by 5 mg and two subjects ages 9 and 15 years
originally assigned placebo whose lisinopril doses were
increased by 2.5 mg.
Safety profile
Potassium levels at entry into the extension trial averaged
4.0 ± 0.3 mmol/L; a plot of serial potassium values in the
11 subjects is shown in Fig. 1. Median of change in po-
tassium level over 36 months was -0.2 mmol/L in the 6
subjects initially on placebo and 0.2 mmol/L in the 5
who were on eplerenone from the beginning. One
subject initially on placebo during the RCT had a 13-
month (1 month after starting open-label eplerenone)
potassium level of 5.7 mmol/L with concern regarding
hemolysis; this prompted temporary cessation of study
medication that was resumed after repeat measure-
ment showed a level of 3.7 mmol/L. Another subject
reported discolored urine that resolved after discon-
tinuation of background idebenone therapy. There
were no episodes of hospitalization, arrhythmia, heart
failure, or death.
Follow-up efficacy data
After an initial 12 months on placebo, younger boys
realized significant improvement in LV strain (i.e. more
negative) over the first 12 months of open-label exten-
sion therapy (median change -4.0%, IQR -4.3 to -2.9%)
that persisted over the 24-month extension period (me-
dian change -4.4%, IQR -5.8 to -0.9%). The older boys
who were on eplerenone during the initial double-blind
12 months maintained strain over the subsequent 12-
month open label extension period (median change
-0.3%, IQR -1.2 to 0.3%). This stability was retained over
the 24-month extension period (median change 0.2%,
IQR -1.1 to 4.3%). The strain improvement realized in
the younger boys was significantly better compared to
the stability or lack of continued improvement in the
older boys (p = 0.0106 for first 12-months of extension
and p = 0.0446 for months 13-24 of extension; Fig. 2).
LV EF was relatively stable over an extension period of
12 months (younger boys initially on placebo: median
change -1.9%, IQR -2.3 to 1.5%; older boys initially on
eplerenone: median -1.2%, IQR -5.0 to 2.2%; p = 0.7150)
and 24 months (younger boys initially on placebo: me-
dian change 2.7%, IQR 1.4 to 3.8%; older boys initially
on eplerenone: median change -1.2%, IQR -7.9 to 1.0%;
p = 0.0541). This EF stability reflected a median change
over 24 months in end-diastolic volume of 16.7 mL
(IQR 10.3 to 29.5 mL) in younger boys initially on pla-
cebo vs. 4.2 (IQR 2.8 to 13.0 mL) in older boys initially
on eplerenone (p = 0.1003); the median change in end-
systolic volumes in the two groups were 5.3 mL (IQR 0.6
Fig. 1 Safety. Serial potassium values from baseline through the end of the 36-month open label extension period are shown; black lines indicate
younger subjects who were on placebo and gray lines were older subjects on eplerenone during the initial 12-month double blind RCT. One
result in a subject initially on placebo was 5.7 mmol/L (*) at 13 months (1 month after starting open-label eplerenone); this was repeated and
found to be 3.7 mmol/L. Potassium level in a hemolyzed sample at the 36 month visit was 5.3 mmol/L (**)
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to 17.5 mL) and 4.7 mL (IQR 4.2 to 4.8 mL) (p > 0.9999),
respectively.
Similar patterns of change were observed in LGE over
the extension period in 12 months (younger boys initially
on placebo: median change -0.5 segments, IQR -1.0 to 1.0
segments; older boys initially on eplerenone: median -1.0
segment, IQR -1.0 to -1.0 segments; p = 0.6304) and in 24
months (younger boys initially on placebo: median 0 seg-
ments, IQR 0 to 2.0 segments; older boys initially on
eplerenone: median 0 segments, IQR -2.0 to 1.0 segments;
p = 0.5637).
Discussion
In this 24-month open label extension study, we found a
striking benefit on cardiac function in young boys with
DMD. While the sensitive marker of subclinical cardiac
dysfunction LV strain was also stabilized in older boys,
the benefit was attenuated compared to that seen with
eplerenone therapy at a younger age though still with
stabilization in strain compared to the previously re-
ported decline without therapy [11]. The older subjects
happened to be those who had already received eplere-
none during the prior 12 month double-blind trial, and
may have already realized the largest magnitude of bene-
fit by adding MRA therapy to background ACEI or ARB.
Importantly, no subjects experienced an adverse potas-
sium level, the primary safety concern that has emerged
from MRA trials in other populations. These results are
the first clinical data of MRA therapy supporting earlier
vs. later institution of treatment, consistent with results
from the DMD mouse that endorsed greater efficacy
with earlier therapy [12]. Our findings expand the litera-
ture endorsing safety of eplerenone for pediatric patients
[9, 13], and amplify a recent recommendation to con-
sider spironolactone for patients with heart failure and
preserved ejection fraction amidst heterogeneous trial
data [14].
In using an LVEF cutoff of ≥45% for baseline enroll-
ment, we sought to enroll subjects with preserved EF;
this may not equate to a ‘normal’ CMR EF per reference
values for healthy children and adults (Sarikouch 2010,
Kawel-Boehm 2015). Patients with heart failure with
preserved EF (HFpEF) have very distinct responses to
conventional medical therapies compared to those with
heart failure and reduced EF (HFrEF) (Yancy 2013), and
the early DMD cardiomyopathy phenotype is more con-
sistent with preserved EF. Thus, this cutoff allows our
trial results to align with the limited but growing body
of evidence relevant to treatment decision-making for
boys with early DMD cardiomyopathy.
The parent RCT required evident myocardial injury as
seen by LGE-CMR for enrollment; thus, we cannot
speculate as to the potential efficacy in boys who are still
LGE-negative. Future trials targeting DMD boys at the
time of diagnosis may be warranted. We also recognize
the exciting potential for emerging genetic therapies to
treat the underlying defect. While such therapies con-
tinue to expand beyond the small range of target muta-
tions for which they are presently effective and require
further optimization to deliver myocardial benefit, MRA
therapy may offer a safe therapeutic approach to cardio-
protection. The small sample and effect sizes of this study
of a rare disease for which there are a number of active
enrolling trials of alternate therapies is a limitation, as is
heterogeneity in background medication use, though the
results suggest benefit without significant risk.
Fig. 2 Efficacy. Serial left ventricular circumferential strain values from baseline through the end of the 36-month open label extension period are
shown; black lines indicate younger subjects who were on placebo and gray lines were older subjects on eplerenone during the initial 12-month
double blind RCT
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Conclusions
In conclusion, younger boys treated with eplerenone
realize a significant improvement in LV systolic function
over 24 months of therapy. Older boys whose therapy
was continued for an additional 24 months showed no
significant worsening in LV systolic function with this
treatment. Early MRA therapy in boys with DMD war-
rants consideration to achieve the greatest likelihood of
cardiac benefit.
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